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seen in fibroblasts is a marker for a particular state of differ-
e n t iation expressed by the cells in lattices or in normal human 
dermis, which may be dependent for its expression on some 
interaction with the s wTounding collagen matrix. 
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Previous s tudies of exposure of normal skin to ultra-
violet radiation have demonstrated a cumulative effect 
lasting greater than 24 h when r epeated suberythemal 
exposures are given. However, the time course of recov-
ery from a single suberythemal dose of ultraviolet A 
(UV A) or ultraviolet B (UVB) has not been determined. 
We show here for the first time that the period required 
for recovery of normal skin (as measured by delayed 
erythema) following a single suberythemal dose of UV A 
is between 30 and 48 h, and for UVB is between 24 and 
30 h. Photoprotection was noted for both UV A and UVB 
from the fifth through the ninth day after the single 
suberythemal exposure, but was only statistically sig-
nificant on the fourth day after UVB exposure. 
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Abbreviations: 
MED: minimal erythema dose 
T 0: first irradiation time 
UV A: ul traviolet A 
UVB: ultraviolet B 
The curve depicting recovery from a single subery-
themal dose of UV A or UVB from the first irradiation 
time through the fourth day after irradiation may be 
described as an exponential decay curve. Formulas are 
given for both UV A and UVB which describe the expo-
nential nature of this curve. These formulas may be used 
to predict the exact difference in erythema threshold 
between preirradiated and normal skin. From the fourth 
day after exposure to the ninth day, the curve is nearly 
constant. The nature of the recovery curve in the first 4 
days after exposure suggests that an exponential decay 
process occurs in UV A or UVB damage, consistent with 
unstable photoproduct decay, DNA repair, or constitu-
tive enzymatic processes. 
Repeated daily exposure to s uberythemal UV A (320-400 nm) 
and UVB (290-320 nm) lea ds t o cumulative alteration of normal 
human skin, manifest by a lowering of the erythema threshold 
dose. In a r ecent study, Kaidbey and Kligma n concluded that 
the time r equired to repair d amage from a single subthreshold 
exposure to UV radiation is probably longer than 24 h , a nd 
possibly longer than 48 h for greater than 0.50 MED (minimal 
erythema dose, the least . exposure dose causing a minimal 
erythema with 4 definite borders) [1]. Parrish et a] found that 
subthreshold exposure doses of either UV A or UVB radiation 
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alter the skin for " periods of days" s uch that th e threshold for 
subsequent UV-induced inflammation is decreased [2]. 
It must be r emembered that erythema is only one compon e n t 
of th e complex response of skin to photon-induced injury. 
Erythema is not even the component of lowest threshold; at 
suberyth emal single exposure doses, t h ere is evidence of epi-
dermal cell death [3], damage to keratinocyte DNA [4] , a nd 
induction of melanin pigmentation [5-7]. 
Althouth the two studies mentioned above demonstrated a 
cumulative effect lasting greater than 24 h when repeated 
exposures are given, the time course of recovery from a single 
suberyth ema1 dose of UV has not bee n determined, and differ-
ences between UV A and UVB have not been studied. There is 
at present no model that predicts how quickly normal skin will 
recover from a single suberythemal dose of UV A or UVB. 
The time comse of recovery from a single suberythemal dose 
of UV radiation is of clinical importance for several reasons. In 
phototherapy for psoriasis, mycosis fungoides, and other der-
matologic disorders, it is standard practice to begin with a 
subthresh old dose fo llowed by daily increments. Cumulative 
effects may be responsible for the benefits observed when 
subthreshold doses are given [8]. The effects of repeated sub-
clinical exposures may also be important in cumulative actinic 
changes such as carcinogenesis and wrinkling. 
This study was designed to determine how long t h e erythema 
threshold dose is lowered fo llowing a single suberyth emal dose 
of UV A or UVB, and to demonstrate a ny differences between 
UV A a nd UVB in the time course of recovery following expo-
sure to these wavebands. 
MATERIALS AND METHODS 
Subjects 
Studies were performed on the untanned back and buttocks of 12 
healthy Caucasians (aged 18-33 years) who were not receiving medi-
cations. These subjects had Type II skin (always burn, sometimes tan 
by history). The subjects were paid volunteers, and informed consent 
was obtained. 
UVA Source 
A 2500 W de xenon arc source (Schoeffel Instruments) with f/ 1.5 
quartz condensing lens system was used. Radiation was filtered through 
6 em of 7% CuS0.,/7% CoSO., aqueous solu tion and a Schott WG335 (1 
mm) filter. The radiation was then projected via a dichroic mirror in a 
uniform (± 10%) circular fie ld using a f/ 4.0 quru·tz lens. The 325-382 
nm irradiance was 25 m W / em", as determined by a cosine-corrected IL 
model SEE 400 UVA detector. With this source, the UVB irradiance 
was at least 5 orders of magni tude less than the UV A irradiance. 
UVB Source 
The UVB source was a 1.2 X 1.2 m planru· bank of clo ely spaced 
fluorescent bulbs (FS40 Westinghouse). UVB irradiance was approxi-
mately 1 m W /cm2, as determined by a cosine-corrected IL model 52 
UVB detector. Uniformity of UVB irradiance was + 5%. 
Preliminary MED Detennina.tion. 
Each subject's MED to the UVA source described above wa deter-
mined using 12 1 em-diameter circulru· sites on glu teal skin , wi th a 
geometrical series of 15% increments in exposm e dose. Each subject's 
MED to the broadband UVB source described above was determined 
using 8 2 X 2 em squru·e sites, also in 15% increments of exposure dose. 
All MED determinations were made 24 h after exposure. Each irradi-
ated site was graded for erythema 24 h after exposure. MED was 
defined as the lowest dose of UV A or UVB that resulted in uniform 
erythema with clearly defined borders. 
Experimental Protocol 
The fo llowing protocol was conducted first for UV A and then fo r 
UVB, on sepru·ate ru·eas of the subject's back. 
At the first irradiation time, T 0, 3 25 x 5 em rectangulru· strips 5 em 
apart on the subj ect's back were irradiated with 0.75 MED of UVA or 
UVB, calculated from the preliminary MED determination. The space 
between the rectangular, irradiated str ips provided control (never pre-
viously irradiated) sites immediately adjacent to the sites irradiated 
with 0.75 MED. 
Immediately following the exposure to 0. 75 MED of UV A and UVB, 
both the preirradiated skin and control sites were irradiated in a 
graduated series of doses, calculated to give exposures above, below, 
and including the MED in each case. Simultaneous exposure to iden-
tical doses of UV in immediately adjacent control and experimental 
sites enabled precise compru·ison of degree of erythema in these sites. 
The range of doses at To in the preirradiated sites was 0.25 MED to 
0.87 MED in 15% increments. The range of doses in the control site at 
T o was 0.25 MED to 1.33 MED, again in 15% increments. 
MED determinat ions on control and preirradiated sites as described 
above were repeated at 0, 12, 24, and 30 h, and 2, 3, 4, 5, 7, and 9 days 
after the t ime of preirradiation, using a new area of the preirradiated 
and control strips for each pair of determinat ions. Each MED was 
graded 24 h after irradiation. As the threshold for erythema gradually 
TABLE I. Statistical comparison at each exposure time of difference, D, in MED between control and preirradiated sites 
T ime (Days) n" IY' Su(' Si:.it/ t./ p value 95% Confidence limits for 0 L, L, 
UVA 
0 10 39.61 14.56 4.61 8.59 «.001 29.18 50.03 
0.5 9 29.73 14.48 4.83 6.16 « .001 18.59 40.87 
1 10 18.22 10.63 3.36 5.42 « .001 10.62 25.82 
1.25 6 18.91 16.60 6.78 2.79 .02 < p < .05 1.48 36.34 
2 9 5.68 7.56 2.52 2.25 > .05 -0.13 11.49 
3 8 0.87 2.47 0.87 1.00 > .05 - 1.19 2.94 
4 7 0.39 4.84 1.83 0.213 > .05 -4.09 4.86 
5 7 -5.28 9.03 3.41 -1.55 > .05 -13.62 3.06 
7 6 -1.04 2.55 1.04 -1.00 > .05 -3.71 1.63 
9 5 -2.30 5.14 2.30 -1.00 > .05 -8.68 4.08 
UVB 
0 10 28.55 13.39 4.24 6.73 « .001 18.96 38.1 4 
0.5 11 16.65 10.06 3.03 5.50 «.001 9.90 23.40 
1 11 9.05 8.76 2.64 3.43 .01 > p > .001 3.17 14 .93 
1.25 5 9.30 10.72 4.79 1.94 < .05 -3.99 22.59 
2 11 2.72 7.05 2.12 1.28 < .05 - 2.00 7.44 
3 9 -0.77 5.80 1.93 -0.40 < .05 -5.22 3.68 
4 8 -4.87 5.55 1.96 -2.48 .02 < p < .05 -9.50 -0.24 
5 7 -4.33 10.18 3.85 -1.12 > .05 -13.75 5.09 
7 8 -3.87 9.11 3.22 - 1.20 > .05 - 11.48 3.74 
9 7 -4.06 5.78 2.18 -1.86 > .05 -9.39 1.24 
"n = number of subjects tested. 
"f> = mean difference calcula ted from observed difference in MED between control and experimenta l sites. 
,. so = standard deviation of differences. 
" So = standard error of the differences. 
e t, = D/SB . 
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increased after To in the preirradiated s ites, the doses were gradually 
increased to a range of 0.58 MED to 1.53 MED by Day 3, in order to 
include a site with 1 + erythema. The increment in dosage between sites 
was always 15%. 
Analysis of Data {9} 
A two-tailed t-test for paired comparisons and small sample size with 
unknown population variance was used to test the significance of 
differences in MED between control and preirradiated sites at a ll 
exposure times, for both UVA and UVB. Ninety-live percent confidence 
limits for the mean difference were constructed. Regression analysis 
was used to determine the "best fit" linear regression line. 
RESULTS 
In control skin, i.e., not preirradiated, the mean preliminary 
UVA MEDin 10 subjects was 52.52 J/cm2, with a SD of 12.84 
J / cm2, and a range of 41.6-75 J/cm2 . The mean UVB MEDin 
11 subjects was 43.73 mJ/cm2, with a SD of 19.34 mJ/ cm2, and 
a range of 25-80 mJ/cm2• 
The average dose required at To to produce 1+ erythema 
immediately following 0.75 MED of UVA was 0.34 MED, 
producing a total dose of 1.09 MED at T 0• This result closely 
approximates 1.00 MED within the 15% increments used in this 
study. Similarly, for UVB, the average dose required at To to 
produce 1+ erythema following 0.75 MED of UVB was 0.38 
MED, or a total of 1.13 MED. Again, this result closely approx-
imates 1.00 MED within the 15% increments used in this study. 
Thus, the principle of photoaddition holds at T 0, as expected, 
for both UV A and UVB. 
The raw data and statistical results for differences between 
control and prei.rradiated sites at each time point are given in 
Table I. A graph of th e mean differences between control and 
prei.rradiated sites vs time with 95% confidence limits is shown 
in Figs 1 and 2 for UVA and UVB, respectively. 
For UV A, the t-test for paired comparisons indicates that the 
MED in the prei.rradiated sites is significantly lower (p < .05) 
than the control site only at 0, 12, and 24 h; the differences are 
not significant from 30 h on, with the exception of Day 4. On 
Day 4, the prei.rradiated sites have a significantly higher MED 
than the control sites. 
The data from the regression anova in Figs 3 and 4 indicate 
that a significant portion (p « .001) of the variation in the 
logarithm of the mean difference between control and preina-
diated sites may be attl·ibuted to its regTessi.on on X (time in 
days). 
A t-test of significance of the regression coefficient indicates 
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FIG 1. UV A. Mean difference between control and experimental 
sites (J /cm2 ) vs time (days). Bars indicate 95% confidence limits. Curve 
fitted by eye. See Table I for pertinent statistical data. Mean differences 
· are statistically significant at p < .05 level at time 0, 0.5, 1, and 1.25 
days. 
Vol. 81, No. 1 
~0 
35 
N" 30 
~ 25 
~ 20 
w 
u 15 z ~ 
UJ 10 u.. 
u.. 
0 
~ 
"' 
- 5 
-10 
-15 { 2i.5 0 0.5 2 3 
TIME !DAYS) 
FIG 2. UVB. Mean difference between control and experimental 
sites (mJ/ cm2 ) vs time (days). Bars indicate 95% confidence limits. 
Curve fitted by eye. For pertinent statistical data, see Table I. Mean 
differences are statistically significant at p < .05 level at times 0, 0.5, 
a nd 1 day. 
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Frc 3. UVA. "Best fit" regression line for log D vs time. This is a 
logarithmic transformation of the data in Table I. 
that a highly significant (p « .001) negative regression is 
present for both UV A and UVB. The regression is negative and 
linear when the logarithm of mean difference vs time is plotted 
through Day 4. Thus, the difference in MED between control 
and preinadiated sites may be described as an exponential 
decay curve, with the formula 
DuvA "" 10(- 0.5464t + 1.76) (1) 
and similarly, 
D uvs "" -5.87 + 1o<- o.3r.oac + 1.57) (2) 
where f> is the mean difference between control and prei.rra-
diated sites in J/cm2 (UVA) or mJ/cm2 (UVB) and tis time in 
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days. The mean difference in MED declines toward zero from 
its initial value as time increases. This exponential decay holds 
for both UV A and UVB, from 0 tluough 4 days. From Day 4 
through Day 9, the graph of mean difference in MED vs t ime 
is no longer exponential, but is nearly constant, as may be seen 
in Figs 1 and 2. 
DISCUSSION 
The following conclusions may be drawn from this study 
regarding the reaction of normal skin to a single suberythemal 
(0.75 MED) dose of UV radiation: 
1. The duration of the lowered threshold for delayed ery-
thema is between 30 and 48 h following 0.75 MED of UV A. 
From day 2 (48 h) tluough Day 9, there is no significant 
difference from control in threshold for delayed erythema. 
From Day 5 tlu·ough Day 9, an apparent but not statistically 
significant (p > .05) photoprotection effect occurs in the preir-
radiated sites. 
2. The lowered threshold for delayed erythema following 
0.75 MED of UVB lasts between 24 and 30 h, in contrast to 
UV A. From 30 h on tlu·ough Day 9, there is no significant 
difference from control skin in development of delayed ery-
thema, with the exception of Day 4, when a significant degree 
of photoprotection is observed. As with UV A, a nonsignificant 
photoprotection effect is seen from Day 5 tlu·ough Day 9. 
3. The curve depicting recovery from suberythemal doses of 
UV A and UVB from Day 0 tlu·ough Day 4 may be described as 
an exponential decay curve. The difference in MED between 
control and preirradiated sites at any time between Day 0 and 
Day 4 may be predicted using formulas (1) and (2). From Day 
4 through Day 9, the curve is nearly constant. 
It is interesting to note that in control (never preirradiated) 
skin, the ratio of mean UV A MED to mean UVB MED is 1201, 
which falls between the ratios calculated from two previous 
similar studies, 1170 and 1312 [1,2]. 
Previous investigators theorized from then· work on repeated 
suberythemal doses of UV radiation that a time period of 48 h 
was requn·ed to repan· damage from a single exposure to 0.50 
MED or greater of UVB, and that a longer period of time was 
required to repair damage from UVA [1]. From the results of 
this study, we agree that recovery from the effects of UV A 
takes longer than recovery from UVB. However, we found that 
the recovery time as measured by delayed erythema was be-
tween 30 and 48 h for UV A, and between 24 and 30 h for UVB. 
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FIG 4. UVB. "Best fit" regression line for log (D + 5.87) vs time. 
This is a logarithmic transformation of the data in Table I. 
Several mechanisms have been postulated to explain the 
decrease in tlu·eshold for erythema following a single subery-
themal UV exposure. The fn·st and best-supported mechanism 
is the production and accumulation of biologically significant 
photoproducts which either decay over tin1e or are actively 
repan·ed. These photoproducts may induce an inflammatory 
response if present in sufficient amounts [10]. Suggested targets 
include nucleic acids and proteins (11]. Pyrimidine dimers and 
other products are formed when UV radiation is absorbed by 
nucleic acids (12,13]. Absorption of UV radiation by m embrane 
lipoproteins may lead to membrane breakdown (14]. Unstable 
reactive free radicals may be formed when the chromophore 
absorbs UV radiation [15,16]. The actual target or clu·omophore 
may be any one of these. 
Other postulated, but less likely, mechanisms include (1) 
receptor sensitization by exposure, e.g., blood vessels and mel-
anocytes, (2) alteration of physical or optical properties of the 
skin such that a g1·eater fraction of the incident dose reaches 
viable tissues capable of producing erythema, and (3) alteration 
of release of mediators involved in producing erythema (2]. The 
exponential model of the recovery process found in this study 
argues against the last of these mechanisms, mediator release 
in skin, which has been shown to be more short-lived and 
nonexponential. A more likely correlation is with molecular 
events stimulating induction, release, or synthesis of mediators. 
We noted a greater degree ofphotoprotection with UVB than 
with UV A, particularly on Day 4. Possible mechanisms for this 
photoprotection include melanogenesis and hyperplasia of the 
stratum corneum. UVB is more effective than UV A at inducing 
the combination of new melanogenesis, upward displacement 
but retention of melanin, and thickening of the stratum cor-
neum [17]. In general, a single UVA or UVB n-radiation tends 
to increase the functional activity of the melanocyte only, 
whereas multiple n-radiations stimulate an increase in the num-
ber of melanocytes and epidermal melanin units (10]. The 
thickening of the stratum corneum acts in conjunction with 
melanin in protecting against further UV radiation damage by 
absorbing such radiation. 
The importance of this mathematical model for the time 
course of recovery from suberythemal doses of UVA and UVB 
is twofold. Fn·st, it enables the investigator to predict the 
difference in MED between control skin and preirradiation sites 
at any given time in the first 4 days following exposure. Sec-
ondly, the exponential fit suggests that a random decay process 
occurs in UV A or UVB damage, consistent with unstable pho-
toproduct decay, DNA repan·, or constitutive enzymatic pro-
cesses. 
Further research is needed to elucidate the biologic basis of 
this exponential model. Additional insight may be gained by 
alternative statistical methods of analyzing these data. How-
ever, the data do support an exponential decay model in its 
most general form for recovery of normal skin from a single 
suberythemal dose of UV A or UVB. 
The authors wish to thank Mr. R. Rox Anderson for his helpfu l 
review of this manuscript, and Mr. Paul Levins for his technical 
assistance. 
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